Screener
ARS Pharmaceuticals, Inc. SPRY Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by ARS Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: ARS Pharmaceuticals, Inc.’s 10-Q, filed May 15, 2026.
- Filed
- May 15, 2026, 6:17 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-225142
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Research and development (including related party amounts of $667 and $666, respectively) | 4,336 | 2,952 |
| Selling, general and administrative (including related party amounts of $135 and $124, respectively) | 72,204 | 41,104 |
| Total operating expenses | 82,826 | 45,150 |
| Loss from operations | (60,145) | (37,177) |
| Other income (expense), net: | ||
| Interest income | 1,968 | 3,237 |
| Interest expense (including related party amounts of $122 and $0, respectively) | (2,441) | — |
| Total other (expense) income, net | (473) | 3,237 |
Item 1. Financial Statements
FAQ
- What is ARS Pharmaceuticals, Inc.'s operating income?
- ARS Pharmaceuticals, Inc. (SPRY) reported operating income of -$60.15M in Q1 2026.
- How has ARS Pharmaceuticals, Inc.'s operating income changed year-over-year?
- ARS Pharmaceuticals, Inc.'s operating income decreased by 61.8% year-over-year, from -$37.18M to -$60.15M.
- What is the long-term trend for ARS Pharmaceuticals, Inc.'s operating income?
- Over 2 years (2022 to 2025), ARS Pharmaceuticals, Inc.'s operating income has grown at a 124.8% compound annual growth rate (CAGR), from -$35.52M to -$179.45M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.
Ask your AI about ARS Pharmaceuticals, Inc.'s operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude